49 results on '"Pérez Encinas, Manuel"'
Search Results
2. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study
3. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
4. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study
5. Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
6. Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
7. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
8. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
9. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
10. Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
11. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
12. Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia
13. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
14. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
15. Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model
16. Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models
17. Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience
18. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study
19. Safety of FLT3 inhibitors in patients with acute myeloid leukemia
20. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data
21. Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes
22. Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling
23. Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms
24. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia
25. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study
26. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
27. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives
28. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling
29. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
30. Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis
31. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
32. Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls
33. The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution
34. Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns
35. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
36. Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients
37. Excess Mortality in Polycythemia Vera and Essential Thrombocythemia
38. Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms
39. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes
40. Prognostic risk models for transplant decision-making in myelofibrosis
41. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
42. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
43. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
44. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms
45. Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy
46. Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.
47. Anagrelide Treatment in Early Pregnancy in a Patient with JAK2V617F-Positive Essential Thrombocythemia: Case Report and Literature Review
48. Study of the Relation Between the Time Course of the JAK2V617F Allele Burden and the Clinical Evolution in Patients with Myeloproliferative Neoplasms (MPN); A Single Center Study
49. Autologous Stem Cell Transplantation after FLAG-IDA Chemotherapy for High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemias Secondary to MDS (sAML) Does Not Improve Outcome: A PETHEMA Experience in 103 Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.